Virax Biolabs GroupVRAX
13F holders, Q2 2024 (June 30)7holders +4
5new positions
1sold out
1famous investor
$1.16avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, up 4 from Q1 2024. 5 opened new positions and 1 sold out. The largest holders were Virtu Financial LLC ($33K), HRT Financial LP ($29K) and Renaissance Technologies ($13K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $75K |
| Exits | 1 | $11K |
All 13F filers, Q1 2024 → Q2 2024: 68,102 shares bought and 14,785 shares sold, net +53,317 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Virtu Financial LLC | 0.00% | New | 28,058 | $33K |
| HRT Financial LP | 0.00% | New | 25,672 | $29K |
| Renaissance Technologies | 0.00% | New | 11,001 | $13K |
| UBS Group AG | 0.00% | Add +117.5% | 5,601 | $6K |
| Qube Research & Technologies Ltd | 0.00% | New | 300 | $348 |
| Wells Fargo & Company | 0.00% | No change | 100 | $116 |
| Headlands Technologies LLC | 0.00% | New | 45 | $52 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.